01 Procurement
Tender overview
- Buyer
- Barts Health NHS Trust
- Status
- Complete
- Procurement method
- Direct award
- Category
- Not supplied
- CPV classification
- Not supplied
- Tender period
- Not supplied — Not supplied
Description
CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a new personalised immunotherapy treatment where a patient’s T cells are genetically modified to target cancer cells. The proposed contractor, Bristol Myers Squibb, will supply privately developed CAR T products At the time of writing it is only offered at 8 sites across the UK. The proposed contract is for 5 years with the option to extend by up to a further 5 years. The contract does not commit the Trust to place a minimum or any Order. The price paid to the supplier with be capped at NICE / NHS England approved list prices.
This page represents one OCDS contracting process. Notices can be revised over time. Values may be estimates, award values or contract values and should be read with their displayed stage and date.
02 Awards and contracts
Published award records
Provision of CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) products
- Awarded
- Not supplied
- Award value
- £2,100,000
- Suppliers
- 1
- Signed contract
- Not supplied
03 Organisations
Buyers, suppliers and other parties
Barts Health NHS Trust
20 Churchill Place, Canary Wharf, London, UKI42, E14 5HJ, United Kingdom
GB-PPON PVTL-5832-LMDGBristol Myers Squibb
Arc Uxbridge Sanderson Road, New Denham,, Denham, UKJ13, UB8 1DH, United Kingdom
Companies House 02487574 →Companies House links appear only for explicit GB-COH identifiers. BritDB does not create company links from a similar name or address.
04 Provenance
Source for this process
Contains public sector information licensed under the Open Government Licence v3.0. Official external links are available only on the source transition page.